The earnings call reflected a positive outlook for Exelixis with strong revenue growth, new approvals, and positive clinical trial results. However, there were some challenges including the discontinuation of a head and neck cancer trial and higher gross to net deductions. Overall, strong financial performance and strategic advancements in oncology support a positive sentiment.

Company Guidance

During the Exelixis Second Quarter 2025 Financial Results Conference Call, several key metrics and forward-looking statements were discussed. Exelixis reported total revenues of $568 million, with cabozantinib franchise net product revenues at $520 million, representing a 19% year-over-year growth. The CABOMETYX net product revenues were $518 million, with negligible clinical trial sales included. Gross to net for the cabozantinib franchise was reported at 30.2%, influenced by higher 340B volume, now over 24% of total volume. The company posted a GAAP net income of $184.8 million, or $0.68 per share basic, while non-GAAP net income was $212.6 million, or $0.78 per share basic. Cash and marketable securities at the end of the quarter were approximately $1.4 billion, with $302 million allocated for share repurchases. The company reiterated its full-year 2025 financial guidance and highlighted progress in its oncology pipeline, including positive results from the STELLAR-303 trial in CRC and advancement of zanzalintinib as a potential new oncology franchise.

Strong Revenue Growth

Cabozantinib U.S. franchise net product revenues grew 19% year-over-year to $520 million compared to $438 million in the second quarter of 2024.

New Indication Approval

Ipsen received approval for NET from the European Commission, expected to add to royalty streams.

Positive STELLAR-303 Results

Zanzalintinib plus atezolizumab showed significant improvement in overall survival in colorectal cancer patients versus regorafenib.

Successful Neuroendocrine Tumor Launch

CABOMETYX rapidly gained 35% share in the oral small molecule market for second-line plus neuroendocrine tumors.

Financial Strength

Exelixis reported GAAP net income of $184.8 million with cash and marketable securities around $1.4 billion.

Exelixis (EXEL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EXEL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	0.68 / -	0.4	―	―	―
Jul 28, 2025	2025 (Q2)	0.67 / 0.75	0.77	-2.60% (-0.02)
May 13, 2025	2025 (Q1)	0.36 / 0.62	0.12	416.67% (+0.50)
Feb 11, 2025	2024 (Q4)	0.42 / 0.48	0.27	77.78% (+0.21)
Oct 29, 2024	2024 (Q3)	0.34 / 0.40	0	―
Aug 06, 2024	2024 (Q2)	0.31 / 0.77	0.25	208.00% (+0.52)
Apr 30, 2024	2024 (Q1)	0.22 / 0.12	0.12	0.00% (0.00)
Feb 06, 2024	2023 (Q4)	0.23 / 0.27	-0.09	400.00% (+0.36)
Nov 01, 2023	2023 (Q3)	0.10 / 0.00	0.23	―
Aug 01, 2023	2023 (Q2)	0.15 / 0.25	0.22	13.64% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EXEL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 28, 2025	$44.39	$36.94	-16.78%
May 13, 2025	$36.95	$44.65	+20.84%
Feb 11, 2025	$32.81	$32.80	-0.03%
Oct 29, 2024	$28.73	$32.44	+12.91%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Exelixis (EXEL) report earnings?

Exelixis (EXEL) is schdueled to report earning on Nov 04, 2025, After Close (Confirmed).

What is Exelixis (EXEL) earnings time?

Exelixis (EXEL) earnings time is at Nov 04, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EXEL EPS forecast?

EXEL EPS forecast for the fiscal quarter 2025 (Q3) is 0.68.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing